Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Latest Information Update: 08 Apr 2015
Price :
$35 *
At a glance
- Drugs REGN-1400 (Primary) ; Cetuximab; Erlotinib
- Indications Cancer
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 02 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 09 Nov 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.